Pfizer Reports Results of Revatio (sildenafil citrate) in P-III Study for Persistent Pulmonary Hypertension in the Newborns

Shots:

• The P-III study involves assessing of Revatio (IV) + inhaled nitric oxide (iNO) vs iNO as monothx. in newborn babies with persistent pulmonary hypertension
• The P-III study results did not meet its 1EPs i.e, reduction in the treatment failure rate or time on iNO. The study was part of an EU Pediatric Investigational Plan (PIP)
• Revatio is a PDE-5 inhibitor and has received EC’s approval in Oct’2005 for the treatment of pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity in adults. Additionally, it is approved in the EU & Japan for pediatric PAH

Click here to read full press release/ article | Ref: Pfizer | Image: Economic times